International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Blog - Commentary - Alexander Egeberg - graphic

Alexander Egeberg, MD, PhD, DMSc
Bispebjerg Hospital
Copenhagen, Denmark


Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis. Yiu ZZN, Becher G, Kirby B, et al. JAMA Dermatol. 2022 Jul 6:e222909. doi: 10.1001/jamadermatol.2022.2909. Epub ahead of print. PMID: 35791876; PMCID: PMC9260644.

Why this article was chosen

Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world?


In recent years, clinical trials of drugs, such as interleukin (IL)-17 and IL-23 inhibitors, have shown remarkable levels of sustained long-term clearance of psoriasis. However, a fundamental limitation of clinical trials is that the patients included in such trials are not always representative of patients seen in daily clinical practice. Only about one-third of “real-life” patients are eligible for inclusion in a clinical trial. Moreover, comorbid diseases, physician behaviors, dose modifications, regional guidelines, payer policies, and prescribed co-medication may all influence the effectiveness and safety of biologics in daily clinical practice.

In daily practice, loss of response over time is often observed. Although the reasons are still not fully understood, this degree of “biologic fatigue” appears to differ between the different biologics. The term “drug survival” refers to the probability that a patient will remain on treatment and is a critical proxy measure of effectiveness in real-life settings.

The present study examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data. The authors found that guselkumab had the highest drug survival concerning effectiveness and safety. Notably, the authors also found that the effect of biologic therapy was modified by factors such as the presence of psoriatic arthritis, prior exposure to biologic therapy, current nail psoriasis, and ethnicity, thus highlighting that “one size does not fit all” when it comes to treating psoriasis.

Significantly, however, treatment patterns may change over time, and a patient is more likely to, e.g., discontinue adalimumab in the present day compared with twenty years ago, when alternatives were much more limited. The study adds to the growing list of real-world studies suggesting that novel biologics, such as the IL-23 inhibitor guselkumab, have a higher drug survival in psoriasis. Still, there remains an essential need for “personalized evidence,” i.e., predictors showing which patient profiles will benefit the most from a specific biologic.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Recent Posts

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Albert Duvetorp, MD, PhD

Medical Adherence in Topical Agents in the Context of Psoriasis Patients

Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics

Also Read


Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)

In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.

Read More

Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast

A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.